9 RESULTS
COMMENT Dr. Lary Walker and his team have taken an important step forward in demonstrating for the first time a transgenic (tg) rhesus monkey model of AD, where Aβ plaques and congophilic amyloid angiopathy (CAA) are accelerated by at least 10 years. One of two t
COMMENT and highly infectious. He was always insightful and ready to give his forthright comments and opinions
COMMENT In this elegant and important study, Walsh and colleagues demonstrate, using a variety of complementary methodologies, that PrPC is critical for mediating neurotoxicity related to soluble oligomeric species of amyloid-β, α-syn, and p-tau. They show that s
COMMENT Orexin and melatonin, the elephant in the room. The paper by Pappolla et al. brings attention to several important points regarding the mechanisms of amyloid accumulation: According to conventional concepts of cerebral interstitial fluid (ISF) clearance,
COMMENT I would strongly agree that striking the right balance with stimulation of immunity to effect a beneficial response is critical. Another way of accomplishing this goal is simulation of microglia/macrophages via Toll-like receptors (TLRs, as also suggested
COMMENT This is a most interesting paper. Inadequate clearance of Aβ from the brain is considered to play a critical role in amyloid accumulation of late-onset Alzheimer's disease (LOAD). Despite the research efforts of the last three decades, the role of th
COMMENT The emerging evidence suggests that the role of PS FAD-associated mutations involves not only a gain of negative function via APP processing but also a loss of function. Although there is vast evidence to suggest that APP processing and clearance plays a
COMMENT Okura et al. demonstrated effectiveness of no viral Aβ DNA vaccine in reducing Aβ load in APP23 Tg mice. The vaccine was administered without an adjuvant and appears to elicit no cellular immunity. Therefore, it may be considered safer that AN1792, contai
COMMENT I think this is an excellent and exciting paper. Hopefully, direct imaging of AD pathology is just around the corner for patients. The compounds developed by Dr. Klunk and used by Dr. Hyman work extremely well for in-vivo two-photon work, and show promise
